

## References

I-175

1. Kirzinger L, Boy S, Marienhagen J, et al. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. *PLoS ONE*. 2016;1-14.
2. Hofland J, Herrera-Martinez AD, Zandee WT, et al. Management of carcinoid syndrome: A systematic review and meta-analysis. *Endocr Relat Cancer*. 2019;26(3):R145-R156.
3. McCaffrey N, Asser T, Fazekas B, et. al. Health-related quality of life in patients with inoperable malignant bowel obstruction: Secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. *BMC Cancer*. 202;20(1):1050.
4. Caplin ME, Pavel M, Phan AT, et. al. CLARINET Investigators. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. *Endocrine*. 2021;71(2):502-513.
5. Fisher GA Jr, Wolin EM, Liyanage N, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autogel: Results from a randomized, placebo-controlled, double-blind and 32-week open-label study. *Oncologist*. 2018;23(1):16-24.
6. Octreotide Acetate In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 3, 2022.
7. Lanreotide Acetate In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 25, 2022.
8. Clinical Pharmacology™ Compendium. 2024.Tampa FL: Gold Standard, Inc. Ocreotide.
9. Clinical Pharmacology™ Compendium. 2024.Tampa FL: Gold Standard, Inc. Lanreotide.
10. Micromedex DrugDex Compendium®. 2024.Ocreotide.
11. Micromedex DrugDex Compendium®. 2024.Lanreotide.
12. National Comprehensive Cancer Network (NCCN). Octreotide acetate (Sandostatin). NCCN Drugs and Biologics Compendium®. 2024.
13. National Comprehensive Cancer Network (NCCN). Octreotide acetate (Sandostatin LAR). NCCN Drugs and Biologics Compendium®. 2024.
14. National Comprehensive Cancer Network (NCCN). Lanreotide (Somatuline). NCCN Drugs and Biologics Compendium®. 2024.
15. Somatuline® Depot (lanreotide) for injection [package insert]. Ipsen Biopharmaceuticals, Inc.. Cambridge, MA. Revised 02/2023.
16. Sandostatin® (octreotide acetate), for injection [package insert]. Novartis Pharmaceuticals Corporation. East Hanover, NJ. Revised 11/2023.
17. Sandostatin® LAR Depot (octreotide acetate), for injection [package insert]. Novartis Pharmaceuticals Corporation. East Hanover, NJ. Revised 03/2021.

18. Lanreotide injection, for subcutaneous use [package insert]. Cipla USA Inc. Warren, NJ. Revised 12/2021.